✦ LIBER ✦
Switching from ergot to nonergot dopamine agonists in Parkinson's disease: A clinical series and five-drug dose conversion table
✍ Scribed by Katherine Grosset; Fiona Needleman; Graeme Macphee; Donald Grosset
- Publisher
- John Wiley and Sons
- Year
- 2004
- Tongue
- English
- Weight
- 67 KB
- Volume
- 19
- Category
- Article
- ISSN
- 0885-3185
No coin nor oath required. For personal study only.
✦ Synopsis
Abstract
Of 99 patients on ergot‐derived dopamine agonists informed about possible long‐term side effects, switching to a nonergot was undertaken in 88 (89%). There were adverse events in 26%. After 11 months, 82% were on their switch agonist and 93% were on any agonist. Switching dopamine agonists is feasible in this population. © 2004 Movement Disorder Society